Compare RGCO & NERV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | RGCO | NERV |
|---|---|---|
| Founded | 1912 | 2007 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Oil & Gas Production | Biotechnology: Pharmaceutical Preparations |
| Sector | Utilities | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 249.5M | 210.1M |
| IPO Year | 2005 | 2014 |
| Metric | RGCO | NERV |
|---|---|---|
| Price | $22.50 | $4.20 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 1 | 2 |
| Target Price | ★ $22.70 | $10.50 |
| AVG Volume (30 Days) | 10.1K | ★ 185.4K |
| Earning Date | 05-07-2026 | 05-01-2026 |
| Dividend Yield | ★ 3.93% | N/A |
| EPS Growth | ★ 11.21 | N/A |
| EPS | ★ 1.31 | N/A |
| Revenue | ★ $95,334,212.00 | $41,175,600.00 |
| Revenue This Year | $11.06 | N/A |
| Revenue Next Year | $2.89 | N/A |
| P/E Ratio | $16.79 | ★ N/A |
| Revenue Growth | ★ 12.63 | N/A |
| 52 Week Low | $19.68 | $1.76 |
| 52 Week High | $27.17 | $12.46 |
| Indicator | RGCO | NERV |
|---|---|---|
| Relative Strength Index (RSI) | 41.20 | 43.03 |
| Support Level | $21.94 | $3.80 |
| Resistance Level | $22.63 | $4.59 |
| Average True Range (ATR) | 1.00 | 0.38 |
| MACD | -0.32 | -0.01 |
| Stochastic Oscillator | 11.05 | 28.57 |
RGC Resources Inc is involved in the business of distribution and sale of natural gas to residential, commercial, and industrial customers within its service territory in Roanoke, Virginia, and its surrounding localities. The company also provides certain non-regulated services. The company relies on multiple interstate pipelines to transport natural gas. The company operates in three segments: Gas Utility, which is the key revenue generator; Investment in Affiliates this segment reflects the income generated through the activities of the Company's investment in MVP and Southgate projects and Parent & Other including the unregulated activities of the Company as well as certain corporate eliminations.
Minerva Neurosciences Inc a clinical-stage biopharmaceutical company focused on the development and commercialization of certain proprietary product candidates to treat patients suffering from central nervous system (CNS) diseases. Its product candidate, Roluperidone, is in development for the treatment of negative symptoms in patients diagnosed with schizophrenia. Its Clinical-Stage Programs include Roluperidone and Seltorexant. The company's operations are organized into one operating and reportable segment focused on the development and commercialization of proprietary product candidates to treat patients suffering from CNS diseases.